Synapse-associated protein 90/postsynaptic density-95-associated protein (SAPAP) is expressed differentially in phencyclidine-treated rats and is increased in the nucleus accumbens of patients with schizophrenia

Neuropsychopharmacology

Volumn 28, Issue 10, 2003, Pages 1831-1839

  Kajimoto, Yasuo ^a   Shirakawa, Osamu ^a   Lin, Xian Hao ^a   Hashimoto, Takeshi ^a   Kitamura, Noboru ^b   Murakami, Naoya ^c   Takumi, Toru ^d   Maeda, Kiyoshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c KOBE ROSAI HOSPITAL   (Japan)

^d OSAKA BIOSCIENCE INSTITUTE   (Japan)

Author keywords

Brain; Differential display; Glutamate; NMDA; Phencyclidine (PCP); Schizophrenia

Indexed keywords

PHENCYCLIDINE; POSTSYNAPTIC DENSITY PROTEIN 95; AMINO ACID RECEPTOR BLOCKING AGENT; MESSENGER RNA; NERVE PROTEIN; NEUROLEPTIC AGENT; SAPAP PROTEINS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENE IDENTIFICATION; HUMAN; IMMUNOREACTIVITY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ADULT; AGED; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; NORTHERN BLOTTING; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOTTING, NORTHERN; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NUCLEUS ACCUMBENS; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 0642338932     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300212     Document Type: Article

References (58)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Press: Washington, DC.
2. Berrettini WH (2000). Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol Psychiatry 48: 531-538.
3. Berrettini WH, Ferraro TN, Goldin LR, Weeks DE, Detera-Wadleigh SD, Nurnberger Jr JI et al (1994). Chromosome 18 DNA markers and manic depressive illness: evidence for a susceptibility gene. Proc Natl Acad Sci USA 91: 5918-5921.
4. Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994). D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm 95: 105-111.
5. Chambers RA, Krystal JH, Self DW (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 50: 71-83.
6. Craven SE, Bredt DS (1998). PDZ proteins organize synaptic signaling pathways. Cell 93: 495-498.
7. Detera-Wadleigh SD, Badner JA, Berrettini WH, Yoshikawa T, Goldin LR, Turner G et al (1999). A high-density genome scan detects evidence for a bipolar susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci USA 96: 5604-5609.
8. Dracheva S, Marras SAE, Elhakem SL, Kramer FR, Davis KL, Haroutunian V (2001). N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158: 1400-1410.
9. Gao X-M, Shirakawa O, Du F, Tamminga CA (1993). Delayed phencyclidine-induced alterations in local cerebral glucose utilization. Eur J Pharmacol 241: 7-15.
10. 3H]kainate binding in hippocampus 24 hours after PCP. Neurosci Lett 174: 149-153.
11. Gao X-M, Tamminga CA (1996). Phencyclidine produces changes in NMDA and kainate receptor binding in rat hippocampus over a 48-hour time course. Synapse 23: 274-279.
12. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367-1377.
13. Goff DC, Tsai G, Manoach DS, Coyle JT (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152: 1213-1215.
14. Greifenstein FE, Yoshitake J, DeVault M, Gajewski JE (1958). A study of 1-aryl-cyclohexylamine for anesthesia. Anesth Analg 37: 283-294.
15. Heid CA, Stevens J, Livak LJ, Williams PM (1996). Real time quantitative PCR. Genome Res 6: 986-994.
16. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Kelly D (1996). Double-blind, placebo-controlled crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169: 610-617.
17. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
18. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer J-P (1994). Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151: 1234-1236.
19. Kennedy MB (1998). Signal transduction molecules at the glutamatergic postsynaptic membrane. Brain Res Rev 26: 243-257.
20. Kim E, Naisbitt S, Hsueh Y-P, Rao A, Rothschild A, Craig AM et al (1997). GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules. J Cell Biol 136: 669-678.
21. Kornau H-C, Schenker LT, Kennedy MB, Seeburg PH (1995). Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 269: 1737-1740.
22. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist ketamine in humans: psychotomimetic perceptual cognitive and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
23. Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
24. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (2001). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6: 869-872.
25. Lau L-F, Mammen A, Ehlers ME, Kindler S, Chung WJ, Garner CC et al (1996). Interaction of the N-methyl-D-aspartate receptor complex with a novel synapse-associated protein, SAP102. J Biol Chem 271: 21622-21628.
26. Leveque JC, Macias W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S et al (2000). Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 20: 4011-4020.
27. Liang P, Pardee AB (1992). Differential display of eukaryotic messenger RNA by means of polymerase chain reaction. Science 257: 967-971.
28. Liang P, Pardee AB (1995). Recent advances in differential display. Curr Opin Immunol 7: 274-280.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193: 153-159.
30. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF (1962). Model psychoses and schizophrenia. Am J Psychiatry 119: 61-67.
31. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
32. Meador-Woodruff JH, Healy DJ (2000). Glutamate receptor expression in schizophrenic brain. Brain Res Rev 31: 288-294.
33. Meltzer HY, Holtzman PA, Hassan SZ, Guschwan A (1972). Effects of phencyclidine and stress on plasma CPK and aldolase activity in man. Psychopharmacology 26: 44-53.
34. Meyer JS, Greifenstein FE, DeVault M (1959). A new drug causing symptoms of sensory deprivation. J Nerv Ment Dis 129: 54-61.
35. Naisbitt S, Kim E, Tu JC, Xiao B, Sala C, Valtschanoff J et al (1999). Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23: 569-582.
36. Niethammer M, Kim E, Sheng M (1996). Interaction between the C-terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci 16: 2157-2163.
37. Nishino N, Noguchi-Kuno SA, Sugiyama T, Tanaka C (1986). [3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease. Brain Res 377: 186-189.
38. Nothen MM, Cichon S, Rohleder H, Hemmer S, Franzek E, Fritze J et al (1999). Evaluation of linkage of bipolar affective disorder to chromosome 18 in a sample of 57 German families. Mol Psychiatry 4: 76-84.
39. O'Brien RJ, Lau LF, Huganir RL (1998). Molecular mechanisms of glutamate receptor clustering at excitatory synapses. Curr Opin Neurobiol 8: 364-369.
40. O'Donnell P, Grace AA (1998). Phencyclidine interferes with the hippocampal gating of nucleus accumbens neuronal activity in vivo. Neuroscience 87: 823-830.
41. Ohnuma T, Kato H, Arai H, Faull RLM, McKenna PJ, Emson PC (2000). Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 11: 3133-3137.
42. Okuyama S, Ogawa S, Nakazato A, Tomizawa K (1995). Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci Lett 189: 60-62.
43. Olney JW, Labruyere J, Price MT (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360-1362.
44. Palkovits M (1973). Isolated removal of hipothalamal or other brain nuclei of the rat. Brain Res 59: 449-450.
45. Rosse RB, Fay-McCarthy M, Kendrick K, Davis RE, Deutsch SI (1996). D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacology 19: 444-450.
46. Satoh K, Yanai H, Senda T, Kohu K, Nakamura T, Okumura N et al (1997). DAP-1, a novel protein that interacts with the guanylate kinase-like domains of hDLG and PSD-95. Genes Cells 2: 415-424.
47. Scannevin RH, Huganir RL (2000). Postsynaptic organization and regulation of excitatory synapses. Nat Rev 1: 133-141.
48. Schwab SG, Hallmayer J, Lerer B, Albus M, Borrmann M, Hönig S et al (1998). Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. Am J Hum Genet 63: 1139-1152.
49. Sheng M, Wyszynski M (1997). Ion channel targeting in neurons. Bioessays 19: 847-853.
50. Stine OC, Xu J, Koskela R, McMahon FJ, Geschwend M, Friddle C et al (1995). Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. Am J Hum Genet 57: 1384-1394.
51. Takeuchi M, Hata Y, Hirao K, Toyoda A, Irie M, Takai Y (1997). SAPAPs: a family of PSD-95/SAP90-associated proteins localized at postsynaptic density. J Biol Chem 272: 11943-11951.
52. Tamminga CA (1998). Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12: 21-36.
53. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P et al (1999). Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23: 583-592.
54. Yamamoto BK, Cooperman MA (1994). Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14: 4159-4166.
55. Yao I, Hata Y, Hirao K, Deguchi M, Ide N, Takeuchi M et al (1999). Synamon, a novel neuronal protein interacting wth synapse-associated protein 90/postsynaptic density-95-associated protein. J Biol Chem 274: 27463-27466.
56. Yoshikawa T, Sanders AR, Esterling LE, Overhauser J, Garnes JA, Lennon G et al (1997). Isolation of chromosome 18-specific brain transcripts as positional candidates for bipolar disorder. Am J Med Genet 74: 140-149.
57. Wessinger WD, Owens SM (1991). Phencyclidine dependence: the relationship of dose and serum concentrations to operant behavioral effects. J Pharmacol Exp Ther 258: 207-215.
58. Ziff EB (1997). Enlightening the postsynaptic density. Neuron 19: 1163-1174.